Home / Companies / ArriVent BioPharma, Inc. / 18 Jun 2026
ArriVent BioPharma, Inc.: meeting of 18 Jun 2026
Votes reported on Form N-PX, item by item
72 Form N-PX filers reported votes at the ArriVent BioPharma, Inc. meeting of 18 Jun 2026. Their records fall into 2 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 55.3% of reported votes for; 62 filers withheld from or voted against at least one nominee.
423 vote records from 72 filers. 31 of the 70 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
141 vote records from 72 filers. 0 of the 70 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Auditor |
|---|---|---|
| Vanguard | For | For |
| BlackRock and iShares | For | For |
| Fidelity | For | For |
| Dimensional | Abstain or withhold * | For |
| State Street and SPDR | For | For |
| American Century | Abstain or withhold * | For |
| Invesco | For | For |
| Equitable | Abstain or withhold * | For |
| Charles Schwab | For | For |
| Nuveen and TIAA | Abstain or withhold * | For |
| ProShares and ProFunds | Abstain or withhold * | For |
| John Hancock and Manulife | Abstain or withhold * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For |
| J.P. Morgan | For | For |
| Goldman Sachs | For | For |
| Jackson National funds | Split or no vote | Split or no vote |
| Northern Trust and FlexShares | For | For |
| SEI | Abstain or withhold * | For |
| T. Rowe Price | For | For |
| Lincoln Financial | For | For |
| Voya | Abstain or withhold * | For |
| Nationwide | For | For |
| Victory Capital | Abstain or withhold * | For |
| Brighthouse Funds | Abstain or withhold | For |
| Guggenheim and Rydex | Abstain or withhold * | For |
| Columbia Threadneedle | Abstain or withhold * | For |
| Principal | Abstain or withhold * | For |
| Pacific Life funds | For | For |
| Global X | Abstain or withhold * | For |
| DWS | Abstain or withhold * | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the ArriVent BioPharma, Inc. meeting?
72 Form N-PX filers reported votes at the meeting of 18 Jun 2026. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by ArriVent BioPharma, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for ArriVent BioPharma, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing ArriVent BioPharma, Inc. with a meeting date within three days of 18 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.